Also see: Electronic Arts: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK (

TheStreet

) -- STOCK COMMENTS / EPS CHANGES

Abbott Labs

(ABT) - Get Report

price target cut at Barclays to $55 from $60 on fears of weak Humira sales, Barclays said. Maintain Overweight rating.

Airgas

(ARG)

estimates, target upped at Jefferies. ARG estimates were boosted through 2012, Jefferies said. Company can deliver above-average growth and generates healthy free cash flow. Buy rating and new $70 price target.

Bank of America

(BAC) - Get Report

estimates cut at Oppenheimer through 2012. Company is seeing weaker trading results and higher costs. Perform rating.

BB&T

(BBT) - Get Report

estimates, target raised at Jefferies. Shares of BBT now seen reaching $31, according to Jefferies. Estimates also increased, given improving credit trends. Hold rating.

Cisco Systems

(CSCO) - Get Report

price target higher at Barclays to $24 from $22 on steady markets and stabilizing outlook, Barclays said. Maintain Equal Weight rating.

Eaton

(ETN) - Get Report

estimates, target boosted at UBS. Shares of ETN now seen reaching $106. Estimates also upped, to match the company's new guidance. Neutral rating.

First Solar

(FSLR) - Get Report

added to Conviction Buy List at Goldman. $165 price target. Company is the low-cost provider and earnings visibility is improving.

General Electric

(GE) - Get Report

price target raised at Credit Suisse to $23 from $22 on improving Power data points, Credit Suisse said. Maintain Outperform rating.

General Electric

(GE) - Get Report

numbers upped at Morgan Stanley through 2012, Morgan Stanley said. Company is carrying a lot of momentum into the new year. Overweight rating and new $23 price target.

Hewlett-Packard

(HPQ) - Get Report

numbers raised at Brean Murray. Shares of HPQ now seen reaching $60. Estimates also increased, given higher sales growth potential. Buy rating.

Intuitive Surgical

(ISRG) - Get Report

numbers boosted at Goldman. Shares of ISRG now seen reaching $270, according to Goldman Sachs. Estimates also upped, given higher sales and a lower share count. Sell rating.

MetLife

(MET) - Get Report

estimates, target raised at Citigroup. Shares of MET now seen reaching $54, according to Citigroup. Estimates also increased, given a higher expected ROE. Buy rating.

Merck & Co

(MRK) - Get Report

price target lowered at Barclays to $41 from $43. Products coming out in 2011 and 2012 appear small in revenue upside, Barclays said. Maintain Overweight rating.

Navigators

(NAVG) - Get Report

estimates lowered at Credit Suisse. NAVG 2010 and 2011 EPS estimates reduced to $2.52 and $3.50, respectively. Reducing estimates for reinstatement premiums, Credit Suisse said. Maintain Neutral rating and $49 price target.

Netgear

(NTGR) - Get Report

price target boosted at Barclays to $39 from $36. Expecting strong 4Q10 results due to healthy WiFi trends and solid holiday retail environment, Barclays said. Maintain Overweight rating.

PNC Financial

(PNC) - Get Report

numbers increased at Citigroup. PNC estimates were raised through 2012, Citigroup said. Company has a strong capital position and credit trends are improving. Hold rating and new $70 price target.

Phillips-Van Heusen

(PVH) - Get Report

numbers lowered at Citigroup. Shares of PVH now seen reaching $82, according to Citigroup. Estimates also cut, given gross margin pressures. Buy rating.

Schlumberger

(SLB) - Get Report

estimates, target boosted at Citigroup.Shares of SLB now seen reaching $110, Citigroup said. Estimates also upped, as the company is seeing better North American results. Buy rating.

Suntrust

(STI) - Get Report

estimates, target increased at Jefferies. STI estimates were raised through 2013, Jefferies said. Company is seeing better credit and sales trends. Hold rating and new $32 price target.

Safeway

(SWY)

estimates, target reduced at Citigroup. Shares of SWY now seen reaching $18, according to Citigroup. Estimates also cut, given continued price competition. Sell rating.

AT&T

(T) - Get Report

estimates lowered at Morgan Stanley. T estimates were reduced through 2012, Morgan Stanley said. Company is facing increased wireless competition from VZ. Overweight rating and $32 price target.

Watson Pharmaceuticals

(WPI)

numbers upped at Goldman. WPI estimates were boosted through 2013, Goldman Sachs said. Company has solid earnings visibility. Neutral rating and new $55 price target.

Watson Pharmaceuticals

(WPI)

price target raised at Credit Suisse to $64 from $60. Positive commentary at investor meeting and increased guidance, Credit Suisse said. Maintain Outperform rating.

This article was written by a staff member of TheStreet.